Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.43 |
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 3/20 | 0.42 |
| ▸ | MIF | P14174 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17313366 | 0.88 | HASPIN (0.56) | CES2HASPINPDE4D | |
| SCHEMBL17313365 | 0.88 | HASPIN (0.56) | CES2HASPINPDE4D | |
| SCHEMBL17320400 | 0.84 | TNF (0.37) | CYP19A1CES2HASPINTNFMIF | |
| SCHEMBL17313338 | 0.79 | TNF (0.44) | CYP19A1CES2HASPINTNFPDE4D | |
| SCHEMBL17313335 | 0.79 | TNF (0.44) | CYP19A1CES2HASPINTNFPDE4D | |
| SCHEMBL17313252 | 0.78 | HASPIN (0.54) | CES2HASPINPDE4D | |
| SCHEMBL17313250 | 0.78 | HASPIN (0.54) | CES2HASPINPDE4D | |
| SCHEMBL17313258 | 0.78 | HASPIN (0.54) | CES2HASPINPDE4D | |
| SCHEMBL17313255 | 0.78 | HASPIN (0.54) | CES2HASPINPDE4D | |
| SCHEMBL17321166 | 0.75 | HASPIN (0.47) | CES2HASPINPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376387-B2 | Oxidisable pyridine derivatives, their preparation and use as anti-alzheimer agents | INSA INST NAT DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2016-06-28 | — | — | US | disclosed |
| US-20150353493-A1 | OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS | INSA (INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353493-A1 | OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS | CBR3, CBR1, CYB5R3 | CYP19A1 791/4885CES2 1391/4885HASPIN 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.